GeneOne Life Science Inc
GeneOne Life Science, Inc., a biopharmaceutical company, engages in the research, development, and contract manufacturing of nucleic acid-based biopharmaceuticals. Its small molecule pipeline comprises GLS-1027, which is in Phase I clinical trial for treatment of nephropathy and inflammatory diseases; GLS-1200 that is in Phase II clinical trial to treat Rhinosinusitis; GLS-1027 and GLS-1200, whic… Read more
GeneOne Life Science Inc (011000) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.065x
Based on the latest financial reports, GeneOne Life Science Inc (011000) has a cash flow conversion efficiency ratio of -0.065x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-3.61 Billion) by net assets (₩55.36 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
GeneOne Life Science Inc - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how GeneOne Life Science Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
GeneOne Life Science Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GeneOne Life Science Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Unitron Tech Co Ltd
KQ:142210
|
0.099x |
|
NVR (NVE.SG)
STU:NVE
|
0.084x |
|
DIRTT Environmental Solutions Ltd
PINK:DRTTF
|
0.094x |
|
Realia Business S.A.
LSE:0KBV
|
0.018x |
|
NSTS Bancorp Inc
NASDAQ:NSTS
|
0.036x |
|
Jeil Pharmaceutical Co Ltd
KO:271980
|
0.054x |
|
F & M Bank Corp
OTCQX:FMBM
|
0.069x |
|
Grown Rogue International Inc
OTCQB:GRUSF
|
0.015x |
Annual Cash Flow Conversion Efficiency for GeneOne Life Science Inc (2013–2024)
The table below shows the annual cash flow conversion efficiency of GeneOne Life Science Inc from 2013 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩85.61 Billion | ₩-16.06 Billion | -0.188x | +3.82% |
| 2023-12-31 | ₩111.49 Billion | ₩-21.74 Billion | -0.195x | -46.78% |
| 2022-12-31 | ₩181.47 Billion | ₩-24.11 Billion | -0.133x | -462.98% |
| 2021-12-31 | ₩205.45 Billion | ₩-4.85 Billion | -0.024x | +85.39% |
| 2020-12-31 | ₩98.51 Billion | ₩-15.92 Billion | -0.162x | -206.09% |
| 2019-12-31 | ₩24.06 Billion | ₩-1.27 Billion | -0.053x | +78.64% |
| 2018-12-31 | ₩29.41 Billion | ₩-7.27 Billion | -0.247x | -123.54% |
| 2017-12-31 | ₩36.54 Billion | ₩-4.04 Billion | -0.111x | +68.00% |
| 2016-12-31 | ₩35.85 Billion | ₩-12.39 Billion | -0.346x | -1850.57% |
| 2015-12-31 | ₩39.44 Billion | ₩778.50 Million | 0.020x | +116.49% |
| 2014-12-31 | ₩34.73 Billion | ₩-4.16 Billion | -0.120x | -20.95% |
| 2013-12-31 | ₩23.71 Billion | ₩-2.35 Billion | -0.099x | -- |